Advanced

Real-World Outcome Analysis of Continuously and Intermittently Treated Patients with Moderate to Severe Psoriasis after Switching to a Biologic Agent.

Hjalte, Frida; Steen Carlsson, Katarina LU and Schmitt-Egenolf, Marcus (2015) In Dermatology 230(4). p.347-353
Abstract
Background: Clinical studies of continuous versus intermittent biologic therapy for moderate to severe psoriasis demonstrate improved efficacy with continuous treatment. Objective: To analyse Swedish real-world data of continuously and intermittently treated biologic-naïve patients after switching to a biologic agent. Methods: This is an observational study based on PsoReg, the Swedish registry for systemic psoriasis treatment. Outcome effects in biologic-naïve patients who switched to a biologic agent (n = 351) were analysed in groups of continuous, intermittent and terminated treatment. Results: Intermittently treated patients (n = 50) reported higher Psoriasis Area and Severity Index and Dermatology Life Quality Index values after... (More)
Background: Clinical studies of continuous versus intermittent biologic therapy for moderate to severe psoriasis demonstrate improved efficacy with continuous treatment. Objective: To analyse Swedish real-world data of continuously and intermittently treated biologic-naïve patients after switching to a biologic agent. Methods: This is an observational study based on PsoReg, the Swedish registry for systemic psoriasis treatment. Outcome effects in biologic-naïve patients who switched to a biologic agent (n = 351) were analysed in groups of continuous, intermittent and terminated treatment. Results: Intermittently treated patients (n = 50) reported higher Psoriasis Area and Severity Index and Dermatology Life Quality Index values after switching than patients with continuous (n = 260) or terminated treatment (n = 41). Study Limitations: The reason for intermittent treatment was not recorded. The intermittently treated patients may be a heterogeneous group and a limitation is that it cannot be determined whether less than continuous use was offered to handle negative aspects. Conclusion: Patients with continuous biologic treatment tend to achieve better outcomes compared to intermittently treated patients. © 2015 S. Karger AG, Basel. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Dermatology
volume
230
issue
4
pages
347 - 353
publisher
Karger
external identifiers
  • pmid:25721571
  • wos:000354004000011
  • scopus:84929957277
ISSN
1421-9832
DOI
10.1159/000371881
language
English
LU publication?
yes
id
f9d1a04d-1811-40ce-a57a-4f6c1dc0cbb2 (old id 5142614)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25721571?dopt=Abstract
date added to LUP
2015-03-11 17:17:39
date last changed
2017-01-01 04:09:10
@article{f9d1a04d-1811-40ce-a57a-4f6c1dc0cbb2,
  abstract     = {Background: Clinical studies of continuous versus intermittent biologic therapy for moderate to severe psoriasis demonstrate improved efficacy with continuous treatment. Objective: To analyse Swedish real-world data of continuously and intermittently treated biologic-naïve patients after switching to a biologic agent. Methods: This is an observational study based on PsoReg, the Swedish registry for systemic psoriasis treatment. Outcome effects in biologic-naïve patients who switched to a biologic agent (n = 351) were analysed in groups of continuous, intermittent and terminated treatment. Results: Intermittently treated patients (n = 50) reported higher Psoriasis Area and Severity Index and Dermatology Life Quality Index values after switching than patients with continuous (n = 260) or terminated treatment (n = 41). Study Limitations: The reason for intermittent treatment was not recorded. The intermittently treated patients may be a heterogeneous group and a limitation is that it cannot be determined whether less than continuous use was offered to handle negative aspects. Conclusion: Patients with continuous biologic treatment tend to achieve better outcomes compared to intermittently treated patients. © 2015 S. Karger AG, Basel.},
  author       = {Hjalte, Frida and Steen Carlsson, Katarina and Schmitt-Egenolf, Marcus},
  issn         = {1421-9832},
  language     = {eng},
  number       = {4},
  pages        = {347--353},
  publisher    = {Karger},
  series       = {Dermatology},
  title        = {Real-World Outcome Analysis of Continuously and Intermittently Treated Patients with Moderate to Severe Psoriasis after Switching to a Biologic Agent.},
  url          = {http://dx.doi.org/10.1159/000371881},
  volume       = {230},
  year         = {2015},
}